

NOVA University of Newcastle Research Online

nova.newcastle.edu.au

Chiew, Angela L.; Isbister, Geoffrey K. "A coagulopathic dilemma: snakes or genes", Lancet Vol. 383, Issue 9935, p. 2184 (2014)

Available from: http://dx.doi.org/10.1016/S0140-6736(14)60690-5

Accessed from: http://hdl.handle.net/1959.13/1045908

Title: A coagulopathic dilemma: snakes or genes.

Angela L. Chiew FACEM 1, 2 *

Geoffrey K. Isbister MD 2,3

- 1. Prince of Wales Hospital Clinical School, University of NSW, Randwick, NSW, Australia.
- 2. NSW Poisons Information Centre, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
- 3. School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.

*Corresponding author: Dr Angela L Chiew:

email: angela.chiew@sesiahs.health.nsw.gov.au

Address: Clinical and Experimental Toxicology Unit, Department of Emergency Medicine, Prince of Wales Hospital, Barker Street, Randwick, NSW, 2031, Australia.

Keywords: factor XII deficiency, brown snake, envenoming

A 66 year old male presented in March 2013 to a small hospital in south-west Queensland-Australia, after a snakebite to his index finger. He had a history of haemochromatosis and was on no regular medications. He reported no local or systemic symptoms. Bloods were collected 45min post-bite and he was transferred to a larger hospital. Initial international normalised ratio (INR) and fibrinogen were normal, qualitative D-Dimer was positive but the activated partial thromboplastin time (aPTT) was unrecordable (Figure 1). In the context of an asymptomatic patient with a normal INR, and the D-dimer assumed to be a possible false positive , the elevated aPTT was interpreted as a sampling error.

Six hours post-bite, repeat aPTT was >200sec and INR was normal. A commercial snake venom detection kit from a bite site swab and urine sample were positive for brown snake (*Pseudonaja* spp.) venom. A clinical toxicologist from the Poisons Centre advised not to give antivenom and to observe and repeat pathology investigations given the patient was asymptomatic and laboratory investigations were inconsistent with snakebite coagulopathy. An isolated raised aPTT was not consistent with brown snake venom induced consumptive coagulopathy (VICC),¹ where both INR and aPTT are abnormal. A moderately raised aPTT can occur in black snake (*Pseudechis* spp.) envenoming, but the patient would have symptoms.²

Eleven hours post-bite the patient reported nausea and vomited. Repeat aPTT remained >200sec, but and the INR was 1.4 (Reference range[RR]:0.9-1.2) and fibrinogen 1.6g/L (RR:1.7-4.5). His creatinine doubled from 78µmol/L to 141µmol/L. Further discussion with the toxicologist again raised the possibility of brown snake envenoming with mild VICC, but the unrecordable aPTT and mildly abnormal INR were inconsistent. Black snake envenoming was also unlikely despite the abnormal aPTT, because of mild symptoms and normal creatine kinase. An undiagnosed clotting factor deficiency was considered possible. Antivenom was not given because of the delay post-bite and the fact that it was unclear if the patient was envenomed and by what snake.

At 24 hours post-bite, the quantitative D-dimer was >20mg/L (RR:<0.40), but his INR and creatinine had normalised, consistent with envenoming., Howeverhis aPTT remained >200sec. He was discharged with follow up for possible undiagnosed factor deficiency. Factor studies done two weeks later were all normal except factor XII levels were <0.01U/mL (RR:0.5-1.5). Venom specific enzyme immunoassays were performed on serum collected as part of the Australian snakebite project, which found 1ng/mL of brown snake venom.¹

This is an unusual case of brown snake envenoming in a patient with undiagnosed factor XII deficiency. The unrecordable aPTT and only slightly abnormal INR made the diagnosis difficult, as brown snake envenoming causes VICC due to a prothrombin activator toxin with low factor I, II, V and VIII levels, resulting in equally abnormal INR and aPTT.³ In contrast, black snake envenoming causes an isolated elevated aPTT due to an anticoagulant toxin, but the aPTT is rarely >100sec and patients are systemically unwell.² In this patient the elevated aPTT was due to factor XII deficiency, and the transient mild elevation in INR was due to partial VICC.^{1,3} The abnormal creatinine was consistent with renal toxicity from brown snake envenoming.¹ Antivenom was not administered in the case because the diagnosis only became clear when it was too late to be administered.

Factor XII deficiency is usually an incidental finding and only detected if the patient has coagulation studies. The incidence of severe factor XII deficiency is 0.3%,⁴ and despite the prolonged aPTT it is not associated with spontaneous or major bleeding.⁵ This case demonstrates the interesting complexities of coagulation studies in snake envenoming, and the difficulty with diagnosis which was only made by measuring venom concentrations and clotting factor levels.

Authors Contribution: AC and GI wrote the case report and were involved in the management of the patient.

Conflict of interest statement: none declared by the authors

References:

- 1. Allen GE, Brown SG, Buckley NA, O'Leary MA, Page CB, Currie BJ, et al. Clinical effects and antivenom dosing in brown snake (Pseudonaja spp.) envenoming--Australian snakebite project (ASP-14). PloS one. 2012;7(12):e53188.
- 2. Johnston Cl, Brown SG, O'Leary MA, Currie BJ, Greenberg R, Taylor M, et al. Mulga snake (Pseudechis australis) envenoming: a spectrum of myotoxicity, anticoagulant coagulopathy, haemolysis and the role of early antivenom therapy Australian Snakebite Project (ASP-19). Clinical toxicology (Philadelphia, Pa). 2013 Jun;51(5):417-24.
- 3. Isbister GK, Scorgie FE, O'Leary MA, Seldon M, Brown SG, Lincz LF. Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10). Journal of thrombosis and haemostasis: JTH. 2010 Nov;8(11):2504-13.
- 4. Halbmayer WM, Haushofer A, Schon R, Mannhalter C, Strohmer E, Baumgarten K, et al. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thrombosis and haemostasis. 1994 Jan;71(1):68-72.
- 5. David Gailani ATN. Chapter 139: Rare coagulation factor deficiencies. Hoffman: Hematology: Basic Principles and Practice. 6th. Philadelphia: Elsevier 2013. p. 1981-2.